PARP inhibition and DNA Damage Response (DDR) as therapeutic targets across multiple tumour types
Overview of cancers with NTRK gene fusions , their testing for patients identification and treatments
Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert
every 2 weeks.
New! ESMO Clinical Practice Guidelines: Hereditary Gastrointestinal Cancers
Find all the latest ESMO Guidelines
and
discover the ESMO Guidelines Slide Sets
!
For full access to all OncologyPRO content: daily medwireNews, ESMO books, slides and webcasts... and much more.
Become an ESMO member today!
20 Sep 2019
Adding liver-directed surgery or radiotherapy to chemotherapy improves overall survival for patients with metastatic intrahepatic cholangiocarcinoma
19 Sep 2019
Adding carboplatin to cabazitaxel may improve progression-free survival for patients with metastatic castration-resistant prostate cancer
18 Sep 2019
Patients who receive broad spectrum antibiotics in the month before immune checkpoint inhibitor therapy may have poorer than expected overall...
17 Sep 2019
Phase II study suggests metformin may improve survival for advanced lung cancer patients undergoing EGFR–TKI therapy
16 Sep 2019
Early Selpercatinib findings suggest the selective RET inhibitor is a feasible treatment option in patients with RET fusion-positive non-small-cell...
27-01 Oct 2019, Barcelona, Spain
13-14 Sep 2019, Lyon, France
06-07 Sep 2019, Singapore
04-05 Sep 2019, Singapore, Singapore
30-31 Aug 2019, Barcelona, Spain
23-25 Aug 2019, Oxford, United Kingdom
18-23 Jul 2019, Valencia, Spain
03-04 Jul 2019, Zurich, Switzerland
03-06 Jul 2019, Barcelona, Spain
27-28 Jun 2019, Zurich, Switzerland
18-23 Jun 2019, Lugano, Switzerland
14-15 Jun 2019, Barcelona, Spain
10-11 Jun 2019, Kazan, Russian Federation
17-18 May 2019, Valencia, Spain
10-11 May 2019, Zurich, Switzerland
